TY - GEN
T1 - Therapeutic applications and mechanisms underlying the activity of immunosuppressive oligonucleotides
AU - Klinman, Dennis M.
AU - Tross, Debbie
AU - Klaschik, Sven
AU - Shirota, Hidekazu
AU - Sato, Takeshi
N1 - Copyright:
Copyright 2018 Elsevier B.V., All rights reserved.
PY - 2009/9/1
Y1 - 2009/9/1
N2 - Synthetic oligodeoxynucleotides (ODN) capable of "neutralizing" or "inhibiting" immune responses have been described. This review will focus on the properties of phosphorothioate ODN that mimic the immunosuppressive activity of the repetitive TTAGGG motifs present in mammalian telomeres. These TTAGGG multimers block the production of pro-inflammatory and T helper type 1 cytokines elicited when immune cells are activated by a wide variety of Toll-like receptor ligands, polyclonal activators, and antigens. Several mechanisms contribute to the suppressive activity of such ODN. Ongoing microarray studies indicate that suppressive ODN interfere with the phosphorylation of signal transducer and activator of transcription 1 (STAT1) and STAT4, thereby blocking the inflammation mediated by STAT-associated signaling cascades. In animal models, suppressive ODN can be used to prevent or treat diseases characterized by persistent immune activation, including collagen-induced arthritis, inflammatory arthritis, systemic lupus erythematosus, silicosis, and toxic shock. These findings suggest that TTAGGG multimers may find broad use in the treatment of diseases characterized by over-exuberant/persistent immune activation.
AB - Synthetic oligodeoxynucleotides (ODN) capable of "neutralizing" or "inhibiting" immune responses have been described. This review will focus on the properties of phosphorothioate ODN that mimic the immunosuppressive activity of the repetitive TTAGGG motifs present in mammalian telomeres. These TTAGGG multimers block the production of pro-inflammatory and T helper type 1 cytokines elicited when immune cells are activated by a wide variety of Toll-like receptor ligands, polyclonal activators, and antigens. Several mechanisms contribute to the suppressive activity of such ODN. Ongoing microarray studies indicate that suppressive ODN interfere with the phosphorylation of signal transducer and activator of transcription 1 (STAT1) and STAT4, thereby blocking the inflammation mediated by STAT-associated signaling cascades. In animal models, suppressive ODN can be used to prevent or treat diseases characterized by persistent immune activation, including collagen-induced arthritis, inflammatory arthritis, systemic lupus erythematosus, silicosis, and toxic shock. These findings suggest that TTAGGG multimers may find broad use in the treatment of diseases characterized by over-exuberant/persistent immune activation.
KW - Autoimmunity
KW - Inflammation
KW - Oligonucleotide
KW - Suppressive
KW - Therapy
UR - http://www.scopus.com/inward/record.url?scp=70349453647&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=70349453647&partnerID=8YFLogxK
U2 - 10.1111/j.1749-6632.2009.04970.x
DO - 10.1111/j.1749-6632.2009.04970.x
M3 - Conference contribution
C2 - 19796080
AN - SCOPUS:70349453647
SN - 9781573317580
T3 - Annals of the New York Academy of Sciences
SP - 80
EP - 88
BT - Oligonucleotide Therapeutics Fourth Annual Meeting
PB - Blackwell Publishing Inc.
ER -